Day: June 23, 2025

New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity Rejuva-treated healthy animals exposed to a high fat diet were protected from weight gain and hyperglycemia Data reinforce advancement of RJVA-001 toward first-in-human studies; preliminary clinical data expected in 2026 BURLINGTON, Mass., June 23, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association’s (ADA) 85th Scientific Sessions. The abstract, titled “Single-Dose GLP-1-Based Pancreatic Gene Therapy Prevents Obesity...

12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure Median weight remained stable through 3 months (0.46% / ~ 1 pound weight change within the margin of error for daily weight measurement), compared to expected 5–6% weight regain (10–15 pounds) after stopping GLP-1 therapy Revita continued to demonstrate excellent tolerability profile compared to GLP-1 drugs; treatment-emergent adverse effects were infrequent, mild, and transient Randomized Midpoint Cohort data expected in Q3 2025; Pivotal Cohort data anticipated in H2 2026 BURLINGTON, Mass., June 23, 2025 (GLOBE NEWSWIRE) — Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root...

MILTON, N.Y., June 23, 2025 (GLOBE NEWSWIRE) — Sono-Tek Corporation (Nasdaq: SOTK), a leading developer of ultrasonic precision coating systems, today announced that it has received a $1.12 million order from a long-standing customer in the medical diagnostic testing industry. The customer, a global manufacturer of medical diagnostic platforms, has partnered with Sono-Tek for nearly a decade, deploying over ten of the company’s mid-size ultrasonic coating systems, typically ranging from $110,000 to $150,000 each. This significantly larger new order represents a major evolution in the relationship, demonstrating Sono-Tek’s enhanced capabilities in advanced automation and high-volume product handling. “This order reflects our customer’s confidence in Sono-Tek’s expanding capabilities and exemplifies our strategy to guide customers...

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and body weight reduction with complete preservation of lean mass, outperforming the group given semaglutide alone Icovamenib promoted healthy myotube morphology and diminished drug-induced atrophy in ex vivo 3D-engineered human myotube cultures In severely insulin-deficient patients from the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide at Week 26, three weeks after last doseSAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (Biomea or Biomea Fusion) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the presentation of new preclinical and clinical data for...

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) — Churchill Resources Inc. (“Churchill” or the “Company”) (TSXV: CRI) is pleased to announce that due-diligence sampling on its Black Raven property returned silver assays of up to 395 g/t silver from grab samples, confirming that high-grade Ag, Sb, and Au are present at several prospects. Five grab samples returned silver assays over 150 g/t (4.69 opt), along with high-grade gold, lead and zinc, emphasizing the polymetallic metal assemblage of critical minerals present in the Black Raven vein system, per the summary table and figure below.Sample #   300   304   305   315   321Silver grade (g/t)   153   329   321   251   395Gold grade (g/t)   3.07   7.70   7.79   5.09   2.16Lead grade (%)   3.10   6.47   5.80   8.83   7.34Zinc grade (%)   2.85   4.97   >5.0   >5.0   >5.0Copper...

From OEM Pilots to Production Line: Scaling Solar Power in Commercial Transport West Palm Beach, FL, June 23, 2025 (GLOBE NEWSWIRE) — The solar technology company Sono Group N.V. (OTCQB: SEVCF) (hereafter referred to as “Sono Group” or “Sono”, parent company to Sono Motors GmbH or “Sono Motors”) today issued a shareholder update from George O’Leary, Managing Director and Chief Executive Officer. Dear Shareholders, The past six months have been about one thing: getting it done. After years of engineering, piloting, and positioning, we’re now watching our solar technology move into real commercial use — with real commercial vehicles, real fleets, and real revenue behind it. This progress didn’t happen overnight. It’s the result of over a year of hands-on engineering, close collaboration with OEMs, rigorous testing, and showing,...

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patients Robust central nervous system (CNS) activity; 41% (7/17) confirmed complete response (CR) and 53% confirmed overall response (ORR) in CNS evaluable disease patients by BICR in overall cohort Enrollment of first patient in a randomized, global pivotal Phase 3 (ALPACCA) study in first-line PACC patients expected in the second half of 2025 ArriVent to host virtual webinar today at 8 am ET NEWTOWN SQUARE, Pa., June 23, 2025 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced encouraging additional follow up proof-of-concept data...

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting. The update applies to Illuccix’s third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA’s approval of an expanded label for Pluvicto®2 (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after treatment...